Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal RELB Primary Antibody for IHC - ABIN966960
Pyz, Naidenko, Miyake, Yamamura, Berberich, Cardell, Kronenberg, Herrmann: The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR. in Journal of immunology (Baltimore, Md. : 1950) 2006
Show all 3 Pubmed References
Human RELB Primary Antibody for IHC - ABIN966959
Marienfeld, Berberich-Siebelt, Berberich, Denk, Serfling, Neumann: Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappaB control. in Oncogene 2002
Show all 3 Pubmed References
this study shows that RelB regulates Th17 differentiation in a cell-intrinsic manner
The data indicate that RelB deficiency may be a key pathway underlying allergic airway inflammation, and that dendritic cell-encoded RelB is sufficient to restore control of this inflammation.
RelB role in the dendritic and myeloid cells development
these data support that RelB suppresses cigarette smoke-induced apoptosis, potentially by increasing the AhR (show AHR Antibodies)
results suggest that changes in the relative concentrations of RelB, NIK:IKK1, and p100 (show PATL2 Antibodies) during noncanonical signaling modulate this transitional complex and are critical for maintaining the fine balance between the processing and protection of p100 (show PATL2 Antibodies).
Results suggest that the RelB/NF-kappaB2 pathway regulates T cell migration to autoimmune targets in Sjogren syndrome through TGFbeta (show TGFB1 Antibodies)/TGFbetaR-dependent regulation of CXCL12 (show CXCL12 Antibodies)/CXCR4 (show CXCR4 Antibodies) signaling.
CCR7 (show CCR7 Antibodies) overexpression and RelB knockdown (KD) in imDCs improve skin-graft survival in a murine skin-transplantation model. Transfection with Ad-CCR7 (show CCR7 Antibodies) and RelB KD in imDCs may be an effective approach inducing immune tolerance, thus being potentially valuable for inhibiting allograft rejection.
RelB is processed by CO2 in a manner dependent on a key C-terminal domain located in its transactivation domain. Loss of the RelB transactivation domain alters NF-kappaB (show NFKB1 Antibodies)-dependent transcriptional activity, and loss of p100 (show PATL2 Antibodies) alters sensitivity of RelB to CO2
this study shows that RelB-silencing in dendritic cells generates dendritic cells of tolerogenic properties with immunomodulatory function and appears as potential option of cell-targeted therapy
AhR and NF-kappaB/Rel protein binding profile within the 3'IghRR mediates the inhibitory effects of TCDD on Ig expression and therefore antibody levels.
results suggest that changes in the relative concentrations of RelB, NIK:IKK1, and p100 (show CUX1 Antibodies) during noncanonical signaling modulate this transitional complex and are critical for maintaining the fine balance between the processing and protection of p100 (show CUX1 Antibodies).
Low RELB expression is associated with Prostate Cancer.
NF-kappaB (show NFKB1 Antibodies) RelB protein, but not RelA (show NFkBP65 Antibodies), displayed high expression in Endometrial cancer samples and cell lines.
to elucidate the induced activation of lytic pathway by ionizing radiation, irradiated SNU-719 cells were checked for the RelA (show NFkBP65 Antibodies) and RelB expression by real-time PCR. RelB level showed a dose-dependent enhancement on 2nd and 4th day, whereas only a slight upregulation in RelA (show NFkBP65 Antibodies) is noticed
RelB is processed by CO2 in a manner dependent on a key C-terminal domain located in its transactivation domain. Loss of the RelB transactivation domain alters NF-kappaB (show NFKB1 Antibodies)-dependent transcriptional activity, and loss of p100 (show CUX1 Antibodies) alters sensitivity of RelB to CO2
EZH2 (show EZH2 Antibodies), through a methyltransferase-independent mechanism, promotes the transcriptional activation of the non-canonical NF-kappaB (show NFKB1 Antibodies) subunit RelB
The altered expression of anti-apoptotic gene Bcl-2 (show BCL2 Antibodies) played critical roles in regulating both spontaneous and radiation-induced apoptosis in the presence of RelB knockdown. For the first time, we showed that RelB knockdown significantly attenuated the migration and invasion of DU145 prostate cancer cells, due to the reduction of integrin b-1
Knockdown of ADGRG2 breast cancer cell lines resulted in a strong reduction in cell adhesion and subsequent cell migration which was associated with a selective reduction in RelB.
the role of RelB on lymphocyte development in humans was shown.
In conclusion, DECs show a unique hypo-responsive phenotype to the pro-inflammatory stimulus LPS (show IRF6 Antibodies) in order to control the inflammatory response at feto-maternal interface.
Bovine foamy virus transactivator BTas interacts with cellular RelB to enhance viral transcription.
XRelB can partially substitute for several, but not all, functions of the Dorsal protein in Drosophila embryos.
NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF- kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF- kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. Stimulates promoter activity in the presence of p49- and p50-NF-kappa-B. Neither associates with DNA nor with p65-NF-kappa-B (By similarity).
transcription factor RelB
, v-rel avian reticuloendotheliosis viral oncogene homolog B (nuclear factor of kappa light polypeptide gene enhancer in B-cells 3)
, v-rel reticuloendotheliosis viral oncogene homolog B, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3
, avian reticuloendotheliosis viral (v-rel) oncogene related B
, v-rel reticuloendotheliosis viral oncogene homolog B
, transcription factor RelB homolog